Patent ID: 8906934
Filing Date: 2014-12-09
Classification: A61K,A61N,A61P,C07D

Abstract:
1. A method for treating cell proliferative disorders caused by and/or associated with an altered protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I): wherein G is CH or nitrogen atom; W is an oxygen atom, NR R R R R R R or a pharmaceutically acceptable salt thereof, with the proviso that the following compounds are excluded: 2,5-di(pyridin-4-yl)-thiophene-3-carboxylic acid amide, 2,5-di(pyridin-4-yl)-thiophene-3-carboxylic acid methylamide, 2,5-di(pyridin-4-yl)-4-methyl-pyrrole-3-carboxylic acid amide, 5-pyridin-4-yl-furan-3-carboxylic acid [4-methoxy-3-(4-methyl-piperazin-1-yl)-phenyl]-amide, 5-pyridin-4-yl-furan-3-carboxylic acid (1-methyl-1,2,3,4-tetrahydro-quinolin-7-yl)-amide and N-[2-amino-1-(2,4-dichlorobenzyl)ethyl]-5-[2-(methylamino)pyrimidin-4-yl]thiophene-3-carboxamide, wherein the cell proliferative disorder is selected from the group consisting of cervical cancer, colon cancer, ovarian cancer, pancreatic cancer, breast cancer, ductal breast cancer, epidermal cancer, lung cancer, large cell lung cancer, squamous cell lung cancer, small cell lung cancer, non-small cell lung cancer, thyroid cancer, medullary thyroid cancer, papillary thyroid cancer, astrocitoma, neuroblastoma, glioblastoma, gliosarcoma, melanoma and osteosarcoma.